Celcuity shared on LinkedIn:
“Following the recent FDA approval of our new targeted therapy for patients with HR+/HER2-, PIK3CA wild-type advanced breast cancer, we would like to recognize and thank the community who contributed to the research that made this milestone possible.
Participation in clinical research is essential to advancing our understanding of cancer and enabling the development of new treatment options. We are deeply grateful for the time, trust, and commitment of the patients who made this progress possible.
For more information on this approval, visit here.”
You can also read:
